Abstract
Successful treatment of gonorrhoea is the mainstay of public health control. Cefixime and ceftriaxone, highly active third generation cephalosporins, are today the recommended first-line agents in most countries and azithromycin is a second-line agent. However, there is increasing evidence of decreasing susceptibility and emergence of therapeutic failures. In this report two cases of clinical failure to cefixime are described, one of which additionally shows failure to azithromycin and selection of a less susceptible strain during treatment.
MeSH terms
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use*
-
Azithromycin / administration & dosage
-
Azithromycin / pharmacology
-
Azithromycin / therapeutic use*
-
Cefixime / administration & dosage
-
Cefixime / pharmacology
-
Cefixime / therapeutic use*
-
Drug Resistance, Multiple, Bacterial
-
England / epidemiology
-
Female
-
Gonorrhea / drug therapy*
-
Gonorrhea / epidemiology
-
Gonorrhea / microbiology
-
Humans
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Neisseria gonorrhoeae / drug effects*
-
Neisseria gonorrhoeae / isolation & purification
-
Sexual Partners
-
Treatment Failure
-
Young Adult
Substances
-
Anti-Bacterial Agents
-
Azithromycin
-
Cefixime